These assays have been developed by PPD Laboratories' bioanalytical, biomarker and vaccines sciences labs to run on multiple assay platforms and are compatible with high-throughput liquid handling so they can support large numbers of specimens, attributes that will be critical to the success of COVID-19 trials.
PPD's new molecular assays utilize reverse transcriptase, polymerase chain reaction (RT-PCR), a versatile analysis technique that can aid in the diagnosis of disease and give a measure of gene expression, making it a valuable tool for viral infection studies.
Specifically, these assays will detect SARS-CoV-2, the causative agent of COVID-19, and quantify the number of infectious particles to determine viral load.
These assays target spike proteins that are specific to SARS-CoV-2 and nucleocapsid proteins that are more general to the coronavirus family. The qualitative (RT-PCR) assay targets both spike and nucleocapsid proteins within open read frame 1 (ORF-1).
This assay uses MS2 bacteriophage as a monitor for ribonucleic acid purification. The quantitative RT-PCR assay (RT-qPCR) solely targets nucleocapsid proteins and utilizes human ribonuclease P (RNase P) targets as a purification control.
Two enzyme-linked immunosorbent assays (ELISA) have been developed specifically for vaccine trials to detect immunoglobulin G to full-length recombinant protein, one for spike and the other for nucleocapsid.
These assays can be used to include or exclude subjects from vaccine trials or to monitor antibody production after vaccination.
They are supported by proprietary bioinformatics tools that analyze complex data sets from these high-throughput assays.
PPD Laboratories also has developed a plate-based functional assay to detect anti-spike antibodies in human serum that can prevent infection by disrupting the binding of angiotensin converting enzyme 2 to SARS-CoV-2 spike protein.
The ACE2 binding inhibition assay can be used in COVID-19 therapy trials to detect antibodies that may be essential to neutralising the virus and preventing infection. The PPD Laboratories central lab also is validating molecular and serology in vitro diagnostic assays that are released for commercial use by regulatory agencies to support clinical trials.
PPD's central lab locations allow the company to perform these tests globally.
PPD Laboratories' test portfolio includes more than 1,500 assays, along with a variety of drug characterization methods and bioanalytical analysis tools.
Poolbeg PHarma plc receives notice of allowance for POLB 001 patent
RedHill Biopharma secures USPTO Patent for Talicia, extending protection through 2034
Micron Biomedical names new scientific advisor to CEO
Quanterix partners with leading health networks for Alzheimer's diagnosis advancements
Precision BioSciences reports FDA pre-IND feedback for PBGENE-HBV
VBI to sell manufacturing capabilities and enter new license agreement with Brii Biosciences
Ondine Biomedical's Steriwave shows promise in nasal pathogen reduction
BioSenic expands patent coverage for ATO therapeutic platform
PacBio unveils Nanobind PanDNA kit for enhanced DNA extraction solutions
Sequentify receives funding from Israel Innovation Authority
INOVIO plans BLA submission for INO-3107 as RRP treatment
ImmunityBio secures USD320m investment from Oberland Capital
Poolbeg Pharma prioritises promising RSV drug candidates identified through AI-led analysis
GHIT fund invests JPY500m in antimalarial drug clinical trial